Julianne Bruno - 20 Mar 2025 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
24 Mar 2025, 17:35:07 UTC
Prior SEC filing
18 Mar 2025
Next SEC filing
17 Nov 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
Elizabeth Ryland Waldinger, attorney-in-fact

Key filing fact

Julianne Bruno filed Form 4 for CRISPR Therapeutics AG (CRSP) on 24 Mar 2025.

Key facts

  • This page summarizes Julianne Bruno's Form 4 filing for CRISPR Therapeutics AG (CRSP).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 24 Mar 2025, 17:35.

Change

  • Previous filing in this sequence was filed on 18 Mar 2025.
  • Current net transaction value: -$70,668.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRSP transaction

Common Shares

Options Exercise

Transaction value
Shares
+3,750
Change %
+44%
Price
Shares after
12,258
Date
20 Mar 2025
Ownership
Direct
Footnotes
F1
CRSP transaction

Common Shares

Sale

Transaction value
$70,668
Shares
-1,714
Change %
-14%
Price
$41.23
Shares after
10,544
Date
21 Mar 2025
Ownership
Direct
Footnotes
F2
CRSP holding

Common Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
7,088
Date
20 Mar 2025
Ownership
The Julianne Bruno 2022 GRAT

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRSP transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares
-3,750
Change %
-25%
Price
Shares after
11,250
Date
20 Mar 2025
Ownership
Direct
Underlying class
Common Shares
Underlying amount
3,750
Exercise price
Footnotes
F1, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

Footnote F2

Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

Footnote F3

This restricted stock unit award was granted on March 20, 2024 with respect to 15,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .